Last reviewed · How we verify

129Xe — Competitive Intelligence Brief

129Xe (129Xe) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyperpolarized contrast agent. Area: Pulmonology / Respiratory.

marketed Hyperpolarized contrast agent Pulmonology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

129Xe (129Xe) — Children's Hospital Medical Center, Cincinnati. Xenon-129 is a hyperpolarized noble gas used as a contrast agent for magnetic resonance imaging to visualize lung ventilation and gas exchange.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
129Xe TARGET 129Xe Children's Hospital Medical Center, Cincinnati marketed Hyperpolarized contrast agent
Hyperpolarized xenon Hyperpolarized xenon Oxford University Hospitals NHS Trust marketed Hyperpolarized contrast agent Xenon-129 nuclear spins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyperpolarized contrast agent class)

  1. Children's Hospital Medical Center, Cincinnati · 1 drug in this class
  2. Oxford University Hospitals NHS Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 129Xe — Competitive Intelligence Brief. https://druglandscape.com/ci/129xe. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: